SO-14 Randomized, Phase 3 Study of Tislelizumab Versus Sorafenib As First-Line Treatment for Unresectable Hepatocellular Carcinoma (HCC): RATIONALE-301 Age ≥65 Years Subgroup
ANNALS OF ONCOLOGY（2023）
关键词
Hepatocellular Carcinoma,Treatment,Liver Cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要